Please use this identifier to cite or link to this item:
Interleukin-4 gene expression in Taiwanese correlate with pulmonary tuberculosis and sepsis
|引用:||1. Alms WJ, Atamas SP, Yurovsky VV, White B (1996) Generation of a variant of human interleukin-4 by alternative splicing. Mol Immunol 33:361-370 2. Ameixa C., Friedland JS.. (2001). Down-regulation of interleukin-8 secretion from Mycobacterium tuberculosis-infected Monocytes by interleukin-4 and -10 but not by interleukin-13. Infect Immun 69:2470-2476. 3. Angus D C,Linde-Zwirble W T,Lidicker J,et al. (2001). Epidemiology of severe sepsis in the United States:analysis of incidence,outcome,and associated costs of care(J).Crit Care Med. 29:1303-1310. 4. Arai N, Nomura D, Villaret D, DeWaal MR, Seiki M, Yoshida M, Minoshima S, Fukuyama R, Maekawa M, Kudoh J (1989) Complete nucleotide sequence of the chromosomal gene for human IL-4 and its expression. J Immunol 142:274-282 5. Arinobu Y, Atamas SP, Otsuka T, Niiro H, Yamaoka K, Mitsuyasu H, Niho Y, Hamasaki N, White B, Izuhara K (1999) Antagonistic effects of an alternative splice variant of human IL-4, IL-4delta2, on IL-4 activities in human monocytes and B cells. Cell Immunol 191:161-167 6. Assenmacher, M., M. Lohning, A. Scheffold, S. Richter, J. Miltenyi, J. Schmitz,and A. Radbruch. (1998). Commitment of individual Th1-like lymphocytes to expression of IFN-g vs IL-4 and IL-10. J. Immunol. 161:2825. 7. Atamas SP, Choi J, Yurovsky VV, White B (1996). An alternativesplice variant of human IL-4, IL-4 delta 2, inhibits IL-4-stimulated T cell proliferation. J Immunol 156:435-441. 8. Atamas SP.,* and Barbara White. (1999). Interleukin 4 in Systemic Sclerosis: Not Just an Increase. Clin Diagn Lab Immunol. September; 6(5): 658-659. 9. Barata LT, Ying S, Meng Q, Barkans J, Rajakulasingam K, Durham SR, Kay AB (1998) IL-4- and IL-5-positive T lymphocytes, eosinophils, and mast cells in allergen-induced latephase cutaneous reactions in atopic subjects. J Allergy Clin Immunol 101:222-230 10. Baumhofer JM., Beinhauer BG., Wang JE., et al. (1998). Gene transfer with IL-4 and Il-13 improves survival in lethal ednotoxemia in the mouse and ameliorates peritoneal macrophages immune competence. Eur J Immunol. 28: 610-615. 11. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. (1992). Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Concensus Conference Committee. Chest. 101: 1644-55. 12. Bradding, P., Feather IH., Howarth PH., Mueller R., Roberts JA., Britten K., Bews JPA., Hunt TC., Okayama Y., Heusser CH, et al. (1992). Interleukin 4 is localized to and released by human mast cells. J. Extx Med. 176:1381. 13. Brown MA, Pierce JH, Watson CJ, Falco J, Ihle JN, Paul WE(1987). B cell stimulatory factor-1/interleukin-4 mRNA isexpressed by normal and transformed mast cells. Cell 50:809-818 14. Brown MA., Hural J.. (1997). Functions of IL-4 and control of its express. Crit Rev. Immunol. 17(1):1-32. 15. Cantagrel A., Navaux F., Louber-Lescoulie P., Nourhashemi F., Enault G., Abbal M., Constantin A., Laroche M., Mazieres B.. (1999). Interleukin-1 beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum. 42:1093-1100. 16. Clerici M, Shearer GM.(1993) A Th1→Th2 switch ia s critical step in the etiology of HIV infection. Immunol Today 14: 107-111. 17. Constant S.L., Bottomly K.. (1997). Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 15: 297-322. 18. Defrance T, Aubry JP, Rousset F, Vanbervliet B, Bonnefoy JY, Arai N, Takebe Y, Yokota T, Lee F, Arai K (1987) Human recombinant interleukin 4 induces Fc epsilon receptors (CD23) on normal human B lymphocytes. J Exp Med 165:1459-467 19. Demissie A., Abebe M., Aseffa A., Rook G., Fletcher H., Zumla A., Weldingh K., Brock I., Andersen P., Doherty TM.. (2004) Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. J Immunol.172:6938-6943. 20. Dhead K., Jung-Su C., Ronan AMB., Louise UK., Jamanda AH., Jim FH., Margaret AJ., Graham AWR., and Alimuddin Z. (2005). In Vivo and In Vitro studies of a novel cytokine, interleukin 4 delta 2, in pulmonary tuberculosis. Am J Respir Crit Care Med. 172: 501-508. 21. DiPiro, J. T., T. R. Howdieshell, J. K. Goddard, D. B. Callaway, R. G. Hamilton, and A. R. Mansberger, Jr. 1995. Association of interleukin-4 plasma levels with traumatic injury and clinical course. Arch. Surg. 130:1159- 1162. 22. Dlugoritzky D., Torres A., Rateni L., et al (1997). Circulating profile of Th1 and Th2 cytokines in tuberculosis patients with different degrees of pulmonary involvement FEMS. Immunol Med Microbial. 18(3): 203-207. 23. Fernandez-Botran R, Krammer PH, Diamantstein T, Uhr JW, Vitetta ES (1986) B cell-stimulatory factor 1 (BSF-1) promotes growth of helper T cell lines. J Exp Med 164:580-593 24. Fenhalls, G., A. Wong, J. Bezuidenhout, P. V. Helden, P. Bardin, and P. T. Lukey. (2000). In situ production of g interferon, interleukin-4, and tumor necrosis factor amRNA in human lung tuberculous granuloma. Infect. Immun. 68:2827. 25. Glare EM, Divjak M, Walters E H. (1997). Asthmatic endobronchial biopsies are more likely to express the interleukin-4 splicing variant, IL-4δ2. Resp Crit Care Med. 155:A817. 26. Glare EM, Divjak M, Rolland JM, Walters EH (1999) Asthmatic airway biopsy specimens are more likely to express the IL-4 alternative splice variant IL-4delta2. J Allergy Clin Immunol 104:978-982 27. Gonzales JR, Kobayashi T, Michel J, Mann M, Yoshie H, Melyle J. (2004). Interleukin-4 gene polymorphisms in Japanese and Caucasian patients with aggressive periodontitis. J Clin Periodontol 31:384-389. 28. Hamilton, and AR. Mansberger, Jr. (1995). Association of interleukin-4 plasma levels with traumatic injury and clinical course. Arch. Surg. 130:1159-1162. 29. Helen AF., Patrick O., David J., Philip H., Graham AWR., Alimuddin Z., T. Mark D., Roger H. B and the Vacsel Study Group. (2004). Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4δ2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulation. Immunology. 112: 669 30. Henderson B, Pettipher ER.. (1989). Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol. 75:306-310. 31. Hernandez Pando R, Orozcoe H, Sampieri A, et al. (1996). Correlation between the kinetics of Th1, Th2 cells and pathology in amurinemodel of experimental pulmonary tuberculosis. Immunology. 89:26-33. 32. Howard M, Paul WE (1982). Interleukins for B lymphocytes. Lymphokine Res 1:1-4 33. Huang D, Xia S, Zhou Y, Pirskanen R, Liu L, Lefvert AK. (1998). No evidence for interleukin-4 gene conferring susceptibility to myasthenia gravis. J Neuroimmunol;92:208-211. 34. Hultgren O, Kopf M, Tarkowski A. (1998). Staphylococcus aureus induced septic arthritis and septic death is decreased in IL-4-deficient mice: role of IL-4 as promoter for bacterial growth. J Immunol. 160:5082-5087 35. Hultgren O., Kopf M,m Tarkowski A.. (1999). Outcome of Staphylococcus aureus-triggered sepsis and arthritis in IL-4-deficient mice depends on the genetic background of the host. Eur J Immounol. 29:2400-2405. 36. Hynninen M., Pettila V., Takkunen O., Orko R., Jansson Sten-Erik., Kuusela P., Renkonen R., Valtonen M.. (2003). Predictive value of monocyte histocompatibility leukocyte Antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis. Shock. 20:1-4. 37. Jain-Vora S, LeVine AM, Chroneos Z, et al. (1998). Interleukin-4 enhances pulmonary clearance of Pseudomonas aeruginosa. Infect Immun. 66:4229-4236 38. Jonathan C.. (2002). The immunopathogensis of sepsis. Nature. 420:885-891. 39. Klein SC, Golverdingen JG, Wichen DF van, Bouwens AG, Stuij I, Tilanus MG, Bast EJ, Weger RA de (1996) Expression of two interleukin 4 mRNA isoforms in B lymphoid cells. Cell Immunol 167:259-268 40. Levi M, Van Der Poll T, Ten Cate H, Van Deventer S J H (1997) The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur. J Chin Invest.27(1): 3-9. 41. Lewis DB, Prickett KS, Larsen A, Grabstein K, Weaver M, Wilson CB. (1988). Restricted production of interleukin 4 by activated human T cells. Proc Natl Acad Sci U S A. 24 (85): 9743-9747 42. Lundgren M, Persson U, Larsson P, Magnusson C, Smith CI, Hammarstrom L, Severinson E (1989) Interleukin 4 induces synthesis of IgE and IgG4 in human B cells. Eur J Immunol 19:1311-1315. 43. Mahdad N., Jonathan C.. (2000). Immunopathogenesis of sever sepsis. J R Coll Physicians Lond. 34:432-436. 44. Martins GA., Da Gloria Da Costa Carvalho M., Rocha Gattass C.. (2003). Sepsis: A follow-up of cytokine production in different phases of septic patients. Int J Mol Med. 11:585-591. 45. McCurdy D K, Zaldivar F, Sandborg C, Imfeld K, Berman M. (1998). Interleukin-4 (IL-4) and IL-4 antagonist, IL-4δ2, expression in synovial fluid from patients with juvenile rheumatoid arthritis (JRA). Arthritis Rheum. 41:S100. 46. McDonnell GV, Kirk CW, Hawkins SA, Graham CA. (2002). An evaluation of interleukin genes fails to identify clear susceptibility loci for multiple sclerosis. J Neurol Sci ;176:4-12. 47. McDonough, K., Kress K., and Bloom BR.. (1993). Pathogenesis of tuberculosis: interaction of Mycobacterium tuberculosis with macrophages. Infect. Immun. 61:2763. 48. Melanie JS., Christopher JG., and William GC. (2002). Jaks, STATs, Cytokines, and Sepsis. Clinical and Diagnostic Laboratory Immunology. 9:1153-1159. 49. Miossec P, Chomarat P, Dechanet J, Moreau JF, Roux JP, Delmas P, Banchereau J (1994) Interleukin-4 inhibits bone resorption through an effect on osteoclasts and proinflammatory cytokines in an ex vivo model of bone resorption in rheumatoid arthritis. Arthritis Rheum 37:1715-1722. 50. Mitchell LC, Davis LS, Lipsky PE (1989) Promotion of human T lymphocyte proliferation by IL-4. J Immunol 142:1548-1557 51. Morel PA., and Oriss TB.. (1998). Cross-regulation between Th1 and Th2 cells. Crit. Rev. Immunol. 18:275-303. 52. Mosmann TR(1994). Cytokine patterns during the progression to AIDS. Science 265: 193-194. 53. Mosmann TR, Bond MW, Coffman RL, Ohara J, Paul WE (1986) T-cell and mast cell lines respond to B-cell stimulatory factor 1. Proc Natl Acad Sci U S A 83:5654-5658 54. Murata T, Obiri N I, Puri R K. (1998). Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review). Int J Mol Med. 1:551-557. 55. North, R. J. (1998). Mice incapable of making IL-4 and IL-10 display normal resistance in infection with Mycobacterium tuberculosis. Clin. Exp. Immunol. 113:55-58 56. Oberholzer A, Oberholzer C and Moldawer LL. (2000). Cytokine signaling regulation of the immune response in normal and critically ill states. Crit Care Med 28: N3-N12. 57. Oberholzer A,Oberholzer C,Moldawer L L,et al.(2001). Sepsis syndromes: understanding the role of innate and acquired immunity(J).Shock,16:83-96. 58. Opal SM, DePalo VA. (1999). Anti-inflammatory cytokines. Chest. 117:1162-1172. 59. Palmer, EM., and GA. van Seventer. (1997). Human T helper cell differentiation is regulated by the combined action of cytokines and accessory cell-dependent costimulatory signals. J. Immunol. 15:2654. 60. Parry RG, Gillespie KM, Parnham A, Clark AG, Mathieson PW. (1999). Interleukin-4 and interleukin-4 receptor polymorphisms in minimal change nephropathy. Clin Sci (Colch);96:665-668. 61. Pinsky MR, Vicent J-L, Deviere J, et al. (1993). Serum cytokine levels in human septic shock: relation to multiple-systems organ failure and mortality. Chest 103: 565-575. 62. Porter C M,Clipstone N A. (2002). Sustained NFAT signaling promotes a Th1-like pattern of gene expression in primary murine CD＋4 T cells. J Immunol. 168:4936-4945. 63. Reinout VC., Elvina K., Frank P., Marij L., Bart-Jan K., Ronald HHN. and Jos WM. van der Meer. (2000). Increased production of interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosis is Related to the presence of pulmonary cavities. J. Infect. Dis. 181: 1194-1197 64. Remick DG..(2003). Cytokine therapeutics for the treatment of sepsis: Why has nothing worked? Curr Pharm Des; 9:75-82. 65. Renz H, Domenico J, Gelfand EW (1991) IL-4-dependent upregulation of IL-4 receptor expression in murine T and B cells. J Immunol 146:3049-3055 66. Robinson DS., Ying S., Taylor IK., Wangoo A., Mitchell DM., Kay AB., Hamid Q., Shaw RJ.. (1994). Evidence for a Th1-like bronchoalveolar T-cell subset and predominance of interferon-gamma gene activation inf pulmonary tuberculosis. Am. J Respir Crit Care Med. 149(4):989-993. 67. Romagnani S (1991) Human TH1 and TH2 subsets: doubt no more. Immunol Today 12:256-257 68. Romagnani S.. (1997). The Th1/Th2 paradigm. Immunol Today 18: 263-266 69. Rook GAW., Seah G., Ustianowski A.. (2001). M. tuberculosis: immunology and vaccination. Eur Respir J. 17: 537-557 70. Rousset F, Malefijt RW, Slierendregt B, Aubry JP, Bonnefoy JY, Defrance T, Banchereau J, Vries JE de (1988) Regulation of Fc receptor for IgE (CD23) and class II MHC antigen expression on Burkitt's lymphoma cell lines by human IL-4 and IFNgamma.J Immunol 140:2625-2632. 71. Seah GT, Rook GAW (1999) A sensitive, non-radioactive quantitative method for measuring IL-4 and IL-4delta2 mRNA in unstimulated cells from multiple clinical samples, using nested RT-PCR. J Immunol Methods 228:139-149. 72. Seah GT., Scott GM., Rook GAW.. (2000). Tyep 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J Infect Dis. 181:385-389. 73. Seah GT, Gao PS, Hopkin JM, Rook GA (2001) Interleukin-4 and its alternatively spliced variant (IL-4delta2) in patients with atopic asthma. Am J Respir Crit Care Med 164:1016-1018 74. Seder, RA., Paul WE., Dvorak AM., Sharkis SJ., Kagey- Sobotka A., Niv Y., Finkelman FD., Barbieri SA., Galli SJ., and Plaut M.. (1991). Mouse splenic and bone marrow cell populations that express high-affinity Fce receptors and produce interleukin 4 are highly enriched in basophils. Proa Natl. Acad. Sci. USA. 88:2835. 75. Severinson E, Naito T, Tokumoto H, Fukushima D, Hirano A, Hama K, Honjo T (1987) Interleukin 4 (IgG1 induction factor): a multifunctional lymphokine acting also on T cells. Eur J Immunol 17:67-72 76. Shirakawa T., Deichmann KA., Izuhara K., Xiao-Quan M., Adra CN., Hopkin JM.. (2000). Atopy and asthma: genetic variants of IL-4 and IL-13 signalling. Immuno Today. 21:60-64. 77. Song GY., Chung CS., Chaudry I H., Ayala A.. (2000). IL-4-idnuced activiation of the Stat6 pathway contributes to the suppression of cell-mediated immunity and death in sepsis. Surgery. 128:133-138. 78. Sorg RV, Enczmann J, Sorg UR, Schneider EM, Wernet P (1993) Identification of an alternatively spliced transcript of human interleukin-4 lacking the sequence encoded by exon 2. Exp Hematol 21:560-563 79. Spits H, Yssel H, Paliard X, Kastelein R, Figdor C, Vries JE de (1988) IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures. J Immunol 141:29-36 80. Stuber F., (2001). Effects of Genomic Polymorphisms on the Course of Sepsis: Is There a Concept for Gene Therapy？ J Am Soc Nephrol 12: S60-S64. 81. Surcel HM. (1994) Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine respone of blood lymphocytes to mycobacterial antigens. Immunology. 81(2): 171-176. 82. Ulrich KT., Hien T., Silvia BP., (1998). The Th1-Th2 paradigm in 1998: law of nature or rule with exceptions. Nephrol Dial Transplant 13: 2445-2448. 83. Van der Meer, M.J., Sweep , F., Pesman, G.J., Borm, G.F., & Hermus, A.R. (1995). Synergism between IL-1b and TNF-a on the activity of the pituitary-adrenal axis and on food intake of rats. American Journal of Physiology, 268 (Endorcrinol. Metab. 31), E551-E557. 84. Van Dissel J, Van Langevelde P, Westendorp R, Kwappenberg K, Fr|
IL-4 is a pleiotropic cytokine which exerts its actions on various lineages of hematopoietic and nonhematopoients cells. This cytokine is one of the central regulators of immunity in health and disease states. IL-4 is a 15-kD polypeptide with widespread effects on many cell types and secreted by helper T cell. IL-4 participates in a lot of inflammatory responses. The IL-4δ2 is a naturally occurring splice variant of human IL-4 with exons 1, 3, and 4 in an open reading frame. It is known to antagonize many biological activities of IL-4. Mycobacterial infections are chiefly controlled by cellular immunity that is through to be the activation of infected macrophages by Th1-type cytokines particularly interferon (INF)-γ. Sepsis is a complicated syndrome in which pro-inflammatory and anti-inflammatory cytokines are expressed simultaneously. Many of the components of the innate immune response are cause cell and tissue damage and hence multiple organ failure. However, it is still unclear for the expression of IL-4 and IL-4δ2 in patients with severe sepsis and TB. Does IL-4 gene polymorphism increase the organic susceptibility to inflammability and IL-4 gene expression associate with sepsis or TB？This is we want to discussion. Many factors determined capacity of cytokine production and release; the hereditary factor is a important ones of them. Genomic variations also may affect gene expression profiles, as well as the structure and production of proteins. In this study, we investigate the IL-4 gene expression polymorphism, and we also investigate the quantification of IL-4 and IL-4δ2 mRNA expression by reverse transcription-polymerase chain reaction (RT-PCR) techniques. We observed no significant differences in genotype distribution and allele frequency of the IL-4 gene. But IL-4 and IL-4 δ 2 mRNA expressions were significantly decreased in patients (p<0.05). The IL-4/IL-4δ2 ratio is no significantly lower than controls (p>0.05). These results suggest that there is no association with IL-4 encoding gene polymorphisms in TB and sepsis. Although the expression of IL-4 and IL-4δ2 were decreased in sepsis, they can not be used to predict the outcome of sepsis. Differences in cytokine expression likely determine whether disease progresses, resolves, or becomes latent. Greater IL-4δ2 expression trends to good reason in TB. The ratio of IL-4/IL-4δ2 is as a possible marker of the phase of disease in TB. The relative roles of IL-4 and IL-4δ2 in the pathogenesis of sepsis and TB deserve further investigation.
|Appears in Collections:||化學系所|
Show full item record
TAIR Related Article
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.